Abstract:Background Epithelial to mesenchymal transition (EMT) occurs during cancer cell invasion and malignant metastasis. Features of EMT include spindle-like cell morphology, loss of epithelial cellular markers and gain of mesenchymal phenotype. Activation of the RON receptor tyrosine kinase by macrophage-stimulating protein (MSP) has been implicated in cellular EMT program; however, the major signaling determinant(s) responsible for MSP-induced EMT is unknown. Results The study presented here demonstrates that RSK2, a downstream signaling protein of the Ras-Erk1/2 pathway, is the principal molecule that links MSP-activated RON signaling to complete EMT. Using MDCK cells expressing RON as a model, a spindle-shape based screen was conducted, which identifies RSK2 among various intracellular proteins as a potential signaling molecule responsible for MSP-induced EMT. MSP stimulation dissociated RSK2 with Erk1/2 and promoted RSK2 nuclear translocation. MSP strongly induced RSK2 phosphorylation in a dose-dependent manner. These effects relied on RON and Erk1/2 phosphorylation, which is significantly potentiated by transforming growth factor (TGF)-β1, an EMT-inducing cytokine. Specific RSK inhibitor SL0101 completely prevented MSP-induced RSK phosphorylation, which results in inhibition of MSP-induced spindle-like morphology and suppression of cell migration associated with EMT. In HT-29 cancer cells that barely express RSK2, forced RSK2 expression results in EMT-like phenotype upon MSP stimulation. Moreover, specific siRNA-mediated silencing of RSK2 but not RSK1 in L3.6pl pancreatic cancer cells significantly inhibited MSP-induced EMT-like phenotype and cell migration. Conclusions MSP-induced RSK2 activation is a critical determinant linking RON signaling to cellular EMT program. Inhibition of RSK2 activity may provide a therapeutic opportunity for blocking RON-mediated cancer cell migration and subsequent invasion.

Role of ribosomal S6 kinase family in message patheway

Ribosomal Protein S6 Kinase (RSK)-2 As a Central Effector Molecule in RON Receptor Tyrosine Kinase Mediated Epithelial to Mesenchymal Transition Induced by Macrophage-Stimulating Protein

RSK2 and its binding partners in cell proliferation, transformation and cancer development

ERK/MAPK signalling pathway and tumorigenesis

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

ERK/MAPK Signalling Pathway and Tumorigenesis (Review)

Targeting RSK2 in Cancer Therapy: A Review of Natural Products

Data from Ribosomal S6 Kinase 2 is a Key Regulator in Tumor Promoter–Induced Cell Transformation

ERK1/2 MAP Kinases in Cell Survival and Apoptosis

Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy

The MAPK Signalling Pathways and Colorectal Cancer

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

A Regulatory Mechanism for RSK2 NH(2)-terminal Kinase Activity.

Coupling of the RAS-MAPK Pathway to Gene Activation by RSK2, a Growth Factor-Regulated CREB Kinase

ERK MAP kinase in G1 cell cycle progression and cancer

RSK2 as a key regulator in human skin cancer.

Atypical MAPKs in cancer

Effect of MSK1 and RSK2 Mediated Histone Phosphorylation on Malignant Phenotype of Human Colorectal Cancer Cells